MAY 21, 2018 02:58 PM PDT

Common Antibacterial Chemical may Help Fight Lung Infections

WRITTEN BY: Carmen Leitch

Triclosan is a chemical that was added to many different household and personal products. New research has found that it may help fight deadly illness, including cystic fibrosis (CF), when it is used with another drug that has already been approved by the Food & Drug Administration, tobramycin. CF is a genetic disease impacting about one in every 2,500 to 3,500 people; it causes a buildup of thick mucus in the lungs. That mucus is a magnet for pathogenic bacteria, which thrive in a protective biofilm. When triclosan is combined with tobramycin, it kills cells that protect the CF bacteria.

This is a comparison of the cystic fibrosis bacteria, which becomes a green color under fluorescent light, shown before and after treatment. Far right column -- untreated bacteria. Second column -- bacteria treated with tobramycin alone showing some of the bacteria still remaining. Third column -- bacteria treated with triclosan alone showing the majority of the bacteria still remaining. Far left column -- bacteria treated with tobramycin and triclosan showing the effectiveness of the combination treatment. / Credit: Michigan State University

"The problem that we're really tackling is finding ways to kill these biofilms," said Chris Waters, a microbiology professor. Waters is the lead author of the study reporting these findings in the journal Antimicrobial Agents and Chemotherapy.

Many infections that can be chronic and painful are related to biofilms, said Waters; gingivitis and ear infections are two examples. However, those biofilm-related illnesses can be far more serious too. Aside from the infections seen in CF patients, inflammation of the heart or endocarditis can occur, as can infections in biomedical implants like pacemakers or artificial joints.
 
Waters and colleagues conducted a screen to find compounds that could effectively kill these biofilms. Triclosan emerged as a standout.

"It's well known that triclosan, when used by itself, isn't effective at killing Pseudomonas aeruginosa," said Alessandra Hunt, a post-doctoral associate of microbiology and molecular genetics. "But when I saw it listed as a possible compound to use with tobramycin, I was intrigued. We found triclosan was the one that worked every time."

Triclosan was used for many years until concerns emerged that it was being overused. Because it is so good at treating gingivitis, it is still used in toothpaste. It is also still found in hand sanitizer. It was eliminated from most other products.

Biofilms in CF patients are discussed in the video.

"Limiting its use is the right thing to do," said Michael Maiden, a graduate student in medicine. "The key is to avoid creating resistance to a substance so when it's found in numerous products, the chances of that happening increase."

Tobramycin is the most commonly prescribed CF treatment, but it can’t clear the lungs of infection completely, said Waters. The drug can cause hearing loss and it poses a danger to the kidneys. Even though patients inhale the therapy, they remain chronically infected and eventually have to get a lung transplant, if they can.
 
"Most transplants aren't a viable option though for these patients and those who do have a transplant see a 50 percent failure rate within five years," Waters added. "The other issue is that tobramycin can be toxic itself."

"Our triclosan finding gives doctors another potential option and allows them to use significantly less of the tobramycin in treatment, potentially reducing its use by 100 times," Hunt said.

Michigan State University microbiology professor Chris Waters (pictured left), with research associates Micheal Maiden and Alessandra Hunt, have found that a common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with the already FDA-approved antibiotic tobramycin. /Credit: Derrick Turner

Brushing your teeth with triclosan won’t be enough, Maiden said. But the team wants to test their combination on a mouse model. They are hopeful it will lead to human trials quickly, because both drugs have already been approved.

"We're working to get this potential therapy approved so we can provide a new treatment option for CF patients, as well as treat other biofilm infections that are now untreatable. We think this can save lives."


Sources: AAAS/Eurekalert! Via Michigan State University, Antimicrobial Agents and Chemotherapy

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 04, 2018
Microbiology
JUL 04, 2018
Revealing How Gut Bacteria can Impact our Health
Our GI tract pays host to trillions of microbes, which have been shown to play a highly influential role in our health and well-being....
JUL 27, 2018
Microbiology
JUL 27, 2018
Making Accurate Assessments of the Environmental Impact of Pollution
Without the right experimental design, behavioral testing can easily produce the wrong results....
AUG 02, 2018
Immunology
AUG 02, 2018
Chronic Infections Outsmart the Immune System
Chronic parasitic infection shown to take advantage of a mechanism to sustain infection and induce death of white blood cells essential to immune response....
AUG 06, 2018
Immunology
AUG 06, 2018
Maternal Dengue Immunity Protects Against Infant Zika Infection
Maternal Dengue immunity produces CD8+ T cells that protect against fetal Zika infection preventing zika-related malformations....
SEP 03, 2018
Microbiology
SEP 03, 2018
A Cell Phone for the Microbiome
This work is a step toward bioengineering the microbes in the gut for improved human health....
SEP 25, 2018
Videos
SEP 25, 2018
Post-Hurricane Bacterial Threats
Natural disasters like hurricanes are dangerous when they occur, and their aftermath poses another set of problems....
Loading Comments...